Long non-coding RNA PLK1S1 was associated with renal cell carcinoma progression by interacting with microRNA-653 and altering C-X-C chemokine receptor 5 expression

WEIYUAN LI, DENGKE YANG, YU ZHANG, SHUTIAN ZHAO, DONG LI* and MIN LIU*

Department of Urology, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200336, P.R. China

Received October 7, 2019; Accepted August 11, 2020

DOI: 10.3892/or.2020.7742

Abstract. Renal cell carcinoma (RCC) is the most common type of renal cancer. Long non-coding RNA (IncRNA) has been reported to play a vital role in the development and progression of various types of cancer type. However, the underlying molecular mechanisms of PLK1S1 in regulating RCC progression remain unclear. In the present study, PLK1S1 was upregulated in RCC tissues and cells, and PLK1S1 expression was also significantly elevated in stage IV RCC tissues. Kaplan-Meier analysis showed that patients with high PLK1S1 expression had a shorter overall survival time compared with those with low PLK1S1 expression. Moreover, bioinformatics analysis and luciferase reporter assay demonstrated that PLK1S1 inhibited microRNA (miR)-653 expression by direct interaction. Functional analyses demonstrated that a miR-653 inhibitor promoted short hairpin PLK1S1-attenuated cell proliferation, invasion and sorafenib resistance of RCC cells. In addition, C-X-C motif chemokine receptors 5 (CXCR5) was identified as an effector of PLK1S1/miR‑653-mediated tumorigenesis and drug resistance in RCC cells. Lastly, xenograft experiments demonstrated that PLK1S1 knockdown inhibited tumor growth in vivo. Reverse transcription-quantitative PCR and western blot analysis revealed that PLK1S1 knockdown upregulated the expression level of miR-653, whilst down-regulating the expression level of CXCR5. In conclusion, the present study revealed that PLK1S1 promoted tumor progression and sorafenib resistance in RCC through regulation of the miR-653/CXCR5 axis, which may offer a novel treatment strategy for patients with RCC.

Introduction

Renal cell carcinoma (RCC) is one of the most lethal urological neoplasms, which contributed to ~5% of all malignant carcinomas, worldwide (1). Chemotherapy (such as sorafenib) is one of the primary treatment strategies for RCC (2). However, chemoresistance remains a major cause of cancer recurrence and cancer-associated mortality (3). Therefore, it is important to improve the understanding of RCC pathogenesis and identify novel targets for the development of diagnostic and therapeutic approaches.

Long non-coding RNAs (IncRNAs) are transcripts >200 nucleotides in length, which are not protein coding (4). Accumulating evidence indicates that IncRNAs are involved in the physiological and pathological processes in most types of cancer, such as hepatocellular carcinoma, colorectal cancer and prostate cancer (5,6). In previous reports, IncRNAs have been associated with chemoresistance in cancer, including RCC. For example, Xu et al (9) demonstrated that the knockdown of lncRNA SRLR reduced chemoresistance to sorafenib in RCC cells. PLK1S1 has been reported to be upregulated in tamoxifen-resistant MCF7 cells, lung adenocarcinoma and bone metastasis (10-12). However, the exact mechanisms of PLK1S1 in RCC remains unclear.

MicroRNAs (miRNAs/miRs) are another type of endogenous non-coding RNAs with a length of 22-25 nucleotides, which regulate gene expression at the post-transcriptional level (13). miRNAs have been reported to play vital roles in cell proliferation, apoptosis and metastasis in human cancer (14). For example, miR-296 inhibited cell invasion and migration in esophageal squamous cell carcinoma by targeting STAT3 (15). Recently, miR-653 was found to suppress non-small cell lung cancer and breast cancer tumorigenesis (16,17). Nonetheless, whether miR-653 is involved in RCC remains to be further clarified.

C-X-C chemokine receptors (CXCRs) are a family of cellular G-protein coupled receptors (18). Among the CXCRs, the chemokine receptor CXCR5, which is primarily expressed in B cells and CD4+ T cells, has been associated
with tumorigenesis and progression of various types of cancer, such as breast, prostate and colon cancer (19-21). Recently, Zheng et al (22) reported that CXCR5 was associated with clear cell renal cell carcinoma (ccRCC) progression and predicted poor prognosis, which led to the hypothesis that CXCR5 might be a vital modulator of RCC tumorigenesis. The findings of the present study provide a further understanding into the development of RCC, which may facilitate the development of a novel therapeutic targets in the treatment of RCC.

Materials and methods

Clinical specimens. In total, 33 pairs of RCC tissues and adjacent normal tissues were obtained from patients (19 males and 14 females), who had undergone surgical resection, with a median age of 56 years (range, 31-78 years) between February 2016 and August 2018 at the Shanghai JiaoTong University School of Medicine. Written informed consent was provided from all participators prior to the start of the study. All tissues were instantly frozen in liquid nitrogen, and then stored at -80˚C for further analysis. The clinicopathological data was obtained from the medical records at the Shanghai JiaoTong University School of Medicine. All patients were classified according to Union International Cancer Control and the American Joint Committee on Cancer (23,24). The study was approved by the Ethics Committee of Shanghai JiaoTong University School of Medicine.

The Cancer Genome Atlas (TCGA) analysis. The expression of PLK1S1 and TCGA kidney renal clear cell carcinoma (TCGA-KIRC) clinical data were downloaded from the TCGA data portal (https://tcga-data.nci.nih.gov/tcga/). Patients with corresponding gene expression were included in the present study, while those with missing overall survival data were excluded.

Cell culture. The human RCC cells (ACHN, Cali1, A498 and 786-O), papillary renal cell carcinoma cells (Caki2) and the immortalized renal proximal tubules epithelial cells (RPTEC) were purchased from American Type Culture Collection. Cell culture medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.), and supplemented with 10% fetal bovine serum (FBS) at 37˚C in a humidified atmosphere containing 5% CO2. To generate ACHN and 786-O resistant cell lines (ACHN-R and 786-O-R, respectively), ACHN and 786-O cells were incubated with increasing concentrations of sorafenib (2.5, 5, 10, 20, 40 and 80 µg/ml) for 48 h. For the detection of cell viability, transfected ACHN and 786-O cells were treated with sorafenib (2 µg/ml) for 48 h. Next, cell viability was determined using the CCK-8 assay kit (Dojindo Molecular Technologies, Inc.). Briefly, 10 µl CCK-8 solution was added to each well and incubated for 3 h, and then the absorbance at 450 nm was measured using a microplate reader (Thermo Fisher Scientific, Inc.). IC50 were determined as the concentration of the drug at which sorafenib produced 50% growth inhibition, with higher IC50 values indicated higher chemoresistance potential.

Cell Counting Kit-8 (CCK-8) assay. To determine the IC50 value, ACHN and 786-O cells (1x104 cells/well) were seeded into 96-well plates and then treated with varying concentrations of sorafenib (2.5, 5, 10, 20, 40 and 80 µg/ml) for 48 h. The functional experiments were performed 48 h post-transfection.

Colony formation assay. Transfected RCC cells were seeded in 6-well plates at a density of 200 cells/well. Following culturing for two weeks, PBS (Sigma-Aldrich; Merck KGaA) was used to rinse each well. Subsequently, RCC cells were fixed in 4% paraformaldehyde (Sigma-Aldrich; Merck KGaA), and then stained with 0.5% crystal violet (Sigma-Aldrich; Merck KGaA) both at room temperature for 10 min. The number of colonies were then counted using a light microscope (magnification, x200). Groups of >50 cells were considered a clone.

Matrigel assay. The invasion abilities of the RCC cells were assessed using Transwell chambers (8.0-µm pore size; EMD Millipore) pre-coated with Matrigel for 1 h (Corning Inc.) at room temperature. Transfected cells (8x103) were added to the upper chamber containing 150 µl RPMI-1640 without FBS. In addition, 550 µl RPMI-1640 medium was added to the lower chamber. After 24 h, cells in the upper chamber were removed, and cells in the lower membrane were fixed in 4% paraformaldehyde and stained with 0.1% crystal violet (Beyotime Institute of Biotechnology) both for 20 min at room temperature. Invaded cells were counted in 3 randomly selected visual fields using a light microscope (magnification, x200; Zeiss GmbBH).

Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL). The TUNEL apoptosis kit (Roche Diagnostics GmbH) was used to assess cell apoptosis. In brief, cells were washed with PBS for 5 min, three times and fixed in 4% paraformaldehyde (cat. no. AR1069; Wuhan Boster Biological Technology, Ltd.) at 4˚C for 20 min. The cells were then incubated with the TUNEL enzyme for 60 min at 3˚C. Finally, the fluorescent reaction was counterstained with DAPI (1:1,000 in PBS; Sigma-Aldrich; Merck KGaA) to stain the nucleus for 10 min at room temperature. Antifade mounting medium (cat. no. P0126; Beyotime Institute of Biotechnology) was used. Images from 4 fields of view were used to obtain images with a fluorescent microscope (magnification, x200; Olympus Corporation).
Western blot analysis. Proteins were extracted from transfected RCC cells using RIPA buffer (Thermo Fisher Scientific, Inc.). Protein concentration was measured using the bicinchoninic acid assay (Beyotime Institute of Biotechnology). A total of 10 µg protein/lane were separated using 10% SDS-PAGE (EMD Millipore), and then transferred to PVDF membranes (Bio-Rad Laboratories, Inc.). After blocking with 5% skimmed milk, membranes were probed with primary antibodies against CXCR5 (1:1,000; cat. no. ab133706; Abcam) and anti-GAPDH (1:1,000; cat. no. ab8245; Abcam) overnight at 4˚C. Subsequently, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies, goat anti-mouse IgG, (cat. no. ab205719) and goat anti-rabbit IgG, (cat. no. ab205718) (both 1,100; both from Abcam) at room temperature for 2 h. The protein bands were visualized using an enhanced chemiluminescence kit (Bio-Rad Laboratories, Inc.). GAPDH served as the loading control.

Reverse transcription-quantitative PCR (RT-qPCR). At 48-h post-transfection, total RNA was isolated from tissues and cell lines using TRIzol® (Thermo Fisher Scientific, Inc.). The RNA was reverse transcribed into cDNA using a reverse transcriptase kit (Takara Bio, Inc.) or the TaqMan® miRNA reverse transcription kit (Thermo Fisher Scientific, Inc.) at 37˚C for 15 min. RT-qPCR was performed on the ABI 7900 Detection System (Applied Biosystems; Thermo Fisher Scientific, Inc.). The primers were as follows: PLK1S1 forward, 5'-CCC ACA TTC ACACCGACAGA-3' and reverse, 5'-ACTCTTGCCATGAGC TGTTG-3'; miR-653 forward, 5'-ACCAGCTTCAAACAA GTTCACGT-3' and reverse, 5'-GCTTCCATCTTTACCT TC TGCCA-3'; CXCR5 forward, 5'-CCCTCATGCGCTCTCTCA AG-3' and reverse, 5'-AGGGCAAGATGAGACCGACG-3'; GAPDH forward, 5'-GCACGCTAACGGCTGAGAAC-3'; and reverse, 5'-GCCCTTCTCAAGTGGTGGAAC-3'; U6 forward, 5'-CTCGTCTCGGCAGCACATACTA-3' and reverse, 5'-ACGAATTTCGCGTCTCCTCCGG-3'.

Luciferase reporter assay. StarBase (http://starbase.sysu.edu.cn) online tool was used to predict the potential miRNAs that could bind to PLK1S1, while TargetScan (http://www.targetscan.org) was used to predict the potential downstream target of miR-653. Mutants within the miR-653 binding site were created using the QuikChange II Site Directed Mutagenesis kit (Agilent Technologies, Inc.). The wild-type (WT) and mutant (Mut) PLK1S1 or CXCR5 was sub-cloned into pmirGLO dual-luciferase vector (Shanghai GenePharma Co., Ltd.) to construct PLK1S1-WT/Mut or CXCR5-WT/Mut vectors. Subsequently, PLK1S1-WT/Mut or CXCR5-WT/Mut vectors were co-transfected with NC mimic, miR-653 mimic and miR-653 inhibitor into 293T cells using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). Luciferase activity was evaluated using the Dual-Luciferase Reporter Analysis system (Promega Corporation), following incubation for 48 h. Firefly luciferase activity was normalized to Renilla (Promega Corporation) luciferase gene activity.

Xenograft experiment. A total of 10 male BALB/c-nu nude mice (age, 5 to 6-weeks-old; weight, 18-20 g) were randomly divided into two groups and maintained under 26˚C. 50% relative humidity, with a 12-h light/dark cycle, with ad libitum access to food and water. All in vivo experimental procedures were approved by the Ethics Committee of Shanghai Jiaotong University School of Medicine. The ACHN cells transfected with shNC or shPLK1S1 were subcutaneously injected into the mice. Tumors were examined every 7 days. Mice were euthanized according to the following criteria: i) the weight of the mouse was excessively reduced or increased; ii) abnormal behavior; iii) tumor diameter was >1.5 cm; iv) the tumor was ulcerated. No mouse died or had significant weight loss during the experiment. On 28th day, the mice were sacrificed by cervical dislocation following anesthesia with an intraperitoneal injection of sodium pentobarbital (60 mg/kg). Animal death was confirmed by cardiac and respiratory arrest, muscle relaxation and lack of reflection. The tumors were photographed, and the tumor weights were measured. Tumor volume was calculated using the following formula: Volume = (length x width^2)/2. The maximum tumor volume was 709 mm^3 and the maximum diameter of tumor was 16 mm.

Statistical analysis. Statistical analysis was performed using SPSS v16.0 (SPSS, Inc.). The experiments were performed three times and the data are presented as mean ± standard deviation. Comparisons among multiple groups were performed using one-way analysis of variance, followed by Tukey's post hoc test. Comparison between RCC and adjacent normal tissue samples from patients with RCC was performed using a paired Student's t-test, while comparison between the experimental and control groups was performed using an unpaired Student's t-test. Kaplan-Meier analysis and the log-rank test were used to analyze survival curves. Cut-off values were determined using the mean expression level of PLK1S1. P<0.05 was considered to indicate a statistically significant difference.

Results

PLK1S1 is upregulated in RCC cells and tissues and is associated with poor prognosis. The mRNA expression level of PLK1S1 was investigated in RCC cells, and the results indicated that expression in the RCC cells (Caki1, ACHN, A498 and 786-O) and the Caki2 papillary RCC cell line was significantly upregulated compared with that in the RPTEC cell line (Fig. 1A). Furthermore, the PLK1S1 mRNA expression level was also significantly increased in clinical tissues, (Fig. 1B). In addition, it was found that PLK1S1 expression was associated with histological grade, tumor stage, lymph node metastasis and distant metastasis, while there was no association with age or sex (Table I).

To investigate the mRNA expression levels further, TCGA datasets were analyzed to determine the involvement of PLK1S1 in RCC. The data revealed that PLK1S1 mRNA expression levels in RCC tissues was significantly increased compared with that in adjacent normal tissues (Fig. 1C). In addition, Kaplan-Meier analysis showed that patients with high PLK1S1 mRNA expression level had a shorter overall survival time compared with that
in patients with low PLK1S1 expression (Fig. 1D). Notably, it was also found that the PLK1S1 mRNA expression level was significantly increased in patients with stage IV RCC (F, 3.18; adjusted P=0.0299) (Fig. 1E). Taken together, these data indicated that PLK1S1 might be an oncogene for RCC progression.

**PLK1S1 interacts with miR-653.** Using the StarBase bioinformatics analysis software, PLK1S1 was found to bind to miR-653 via complementary base pairing (Fig. 2A). The results from the luciferase reporter assay indicated that miR-653 mimic significantly reduced luciferase activity of pmirGLO-PLK1S1-WT vectors, whereas the miR-653 inhibitor significantly increased luciferase activity (Fig. 2B). In addition, PLK1S1 was significantly downregulated in shPLK1S1 transfected ACHN cells and significantly upregulated in PLK1S1 overexpressed ACHN cells. The downregulation of PLK1S1 significantly increased the expression of miR-653 whereas the upregulation of PLK1S1 significantly decreased the expression of miR-653 (Fig. 2C). Taken together, these results demonstrated that PLK1S1 inhibited miR-653 expression by direct interaction.

**miR-653 inhibitor rescues PLK1S1 knockdown-attenuated tumorigenesis of RCC cells.** To explore whether miR-653-mediated and PLK1S1-regulated RCC tumorigenesis and progression, stable PLK1S1-knockdown RCC cells (ACHN and 786-O) were generated (Fig. 3A). Subsequently, the miR-653 inhibitor was introduced into shPLK1S1-expressing ACHN and 786-O cells. RT-qPCR showed that the introduction of miR-653 inhibitor significantly reduced shPLK1S1-mediated miR-653 upregulation in RCC cells (Fig. 3B). Matrigel and colony formation assays revealed that the miR-653 inhibitor abrogated the inhibitory effects of PLK1S1 knockdown on the invasion and proliferation of RCC cells (Fig. 3C-F). Based on these results, it was confirmed that miR-653 was involved in PLK1S1-modulated tumorigenesis of RCC cells.

**PLK1S1 knockdown-mediated inhibitory effect on sorafenib resistance is reduced by the miR-653 inhibitor in sorafenib-resistant RCC cells.** To investigate the potential role of PLK1S1 and miR-653 in drug resistance to sorafenib in RCC cells, sorafenib-resistant ACHN (ACHN-R) and
786-O cells (786-O-R) were established. As shown in Fig. 4A and B, the IC50 of sorafenib was significantly increased in ACHN-R and 786-O-R cells, indicating that sorafenib-resistant RCC cells were successfully generated. In addition, the miR-653 inhibitor partially reversed PLK1S1 knockdown-attenuated cell viability in sorafenib-resistant RCC cells under sorafenib treatment (Fig. 4C). Furthermore, PLK1S1 knockdown significantly decreased the IC50 of sorafenib in sorafenib-resistant RCC cells, while miR-653 inhibitor partially reversed shPLK1S1-induced decrease in IC50 values (Fig. 4D and E). The TUNEL assay revealed that the miR-653 inhibitor significantly decreased cell apoptosis in shPLK1S1 sorafenib-resistant RCC cells (Fig. 4F and G). In summary, the data suggested that PLK1S1 enhanced chemoresistance in RCC cells to sorafenib by regulating miR-653.

CXCR5 is a target of miR-653. Using TargetScan (http://www.targetscan.org), CXCR5 was predicted as a downstream target of miR-653 (Fig. 5A). Furthermore, luciferase reporter assay demonstrated that miR-653 mimic reduced luciferase activity of WT CXCR5, while the opposite effect occurred in cells transfected with miR-653 inhibitor (Fig. 5B). In addition, RT-qPCR revealed that miR-653 was significantly upregulated in miR-653 mimic transfected ACHN cells and significantly

| Expression of PLK1S1 | Number | High, n (%) | Low, n (%) | P-value       |
|----------------------|--------|-------------|------------|--------------|
| Clinicopathological features |       |             |            |              |
| Age, years            |        |             |            |              |
| ≤60                   | 15     | 7 (46.7)    | 8 (53.3)   | 0.374        |
| >60                   | 18     | 10 (55.6)   | 8 (44.4)   |              |
| Sex                   |        |             |            |              |
| Male                  | 19     | 9 (47.4)    | 10 (52.6)  | 0.462        |
| Female                | 14     | 8 (57.1)    | 6 (42.9)   |              |
| Histological grade    |        |             |            |              |
| Well                  | 21     | 9 (42.9)    | 12 (57.1)  | 0.011        |
| Moderate and poor     | 12     | 9 (75.0)    | 3 (25.0)   |              |
| Tumor stage           |        |             |            |              |
| I and II              | 20     | 8 (40.0)    | 12 (60.0)  | 0.028        |
| III and IV            | 13     | 9 (69.2)    | 4 (30.8)   |              |
| Lymph node metastasis |        |             |            |              |
| Positive              | 10     | 8 (80.0)    | 2 (20.0)   | 0.011        |
| Negative              | 23     | 11 (47.8)   | 12 (52.2)  |              |
| Distant metastasis    |        |             |            |              |
| Positive              | 11     | 9 (81.8)    | 2 (18.2)   | 0.014        |
| Negative              | 22     | 10 (45.5)   | 12 (54.5)  |              |

Figure 2. PLK1S1 interacts with miR-653. The binding sequences between PLK1S1 and miR-653 were (A) predicted by StarBase and confirmed using (B) a luciferase reporter assay in 293T cells. (C) Reverse transcription-quantitative PCR was used to determine the mRNA expression levels of miR-653 and PLK1S1 in ACHN cells transfected with shNC, shPLK1S1 and pcDNA3.1-PLK1S1. All data are represented as the mean ± SD. *P<0.05; **P<0.01. miRNA, microRNA; sh, short hairpin; NC, negative control.
downregulated in miR-653 inhibitor transfected ACHN cells. The upregulation of miR-653 significantly decreased the expression of CXCR5, while the downregulation of miR-653 significantly increased the expression of CXCR5 (Fig. 5C). Thus, these data indicate that miR-653 directly targets CXCR5.

CXCR5 mediates PLK1S1/miR-653-regulated RCC tumorigenesis. To further determine whether PLK1S1/miR-653 promoted RCC progression through CXCR5, CXCR5 was introduced into shPLK1S1 and miR-653 mimic-expressing ACHN cells. Firstly, it was demonstrated that overexpression of CXCR5 significantly reversed the inhibitory effects of PLK1S1 knockdown and miR-653 overexpression on CXCR5 mRNA expression levels (Fig. 6A and B). Matrigel and colony formation assays demonstrated that the overexpression of CXCR5 significantly reversed the shPLK1S1- and miR-653 mimic-attenuated ACHN cell invasion and proliferation (Fig. 6C-H). Taken together, these data revealed that the PLK1S1/miR-653/CXCR5 axis promoted the development and progression of RCC.

CXCR5 rescues PLK1S1 knockdown- or miR-653 mimic-attenuated chemoresistance of RCC cells. Next, the role of CXCR5 in PLK1S1 and miR-653-modulated drug resistance of

---

Figure 3. miR-653 inhibitor rescues PLK1S1 knockdown-attenuated tumorigenesis of renal cell carcinoma cell lines. Reverse transcription-quantitative PCR was used to determine the mRNA levels of (A) PLK1S1 in ACHN and 786-O cells transfected with shNC and shPLK1S1 and (B) miR-653 in ACHN and 786-O cells transfected with shNC, shPLK1S1, shPLK1S1 plus miR-653 inhibitor. (C) Matrigel assay was used to investigate the invasion ability of ACHN and 786-O cells transfected with shNC, shPLK1S1, shPLK1S1 plus miR-653 inhibitor and the results were subsequently (D) quantified. (E) Colony formation assay was used to determine the colony number of ACHN and 786-O cells transfected with shNC, shPLK1S1, shPLK1S1 plus miR-653 inhibitor and the results were then (F) quantified. All data are represented as the mean ± SD. *P<0.05; **P<0.01. miRNA, microRNA; sh, short hairpin; NC, negative control.
Figure 4. PLK1S1 depletion-mediated inhibitory effect on sorafenib resistance is eliminated by the miR-653 inhibitor in sorafenib-resistant renal cell carcinoma cell lines. (A and B) The IC₅₀ values of sorafenib in ACHN, ACHN-R, 786-O and 786-O-R cells was measured using the CCK-8 assay. CCK-8 was used to determine the (C) cell viability and (D and E) IC₅₀ values of sorafenib of ACHN-R and 786-O-R cells transfected with shNC, shPLK1S1, shPLK1S1 plus miR-653 inhibitor treated with or without 2 µM sorafenib. TUNEL assay was used to investigate cell apoptosis in (F) ACHN-R and (G) 786-O-R cells transfected with shNC, shPLK1S1, shPLK1S1 plus miR-653 inhibitor treated with sorafenib. All data are represented as the mean ± SD. *P<0.05; **P<0.01. miRNA, microRNA; sh, short hairpin; NC, negative control; TUNEL, Terminal deoxynucleotidyl transferase dUTP nick end labeling; CCK-8, Cell Counting Kit-8; R, resistant.
CXCR5 is a target of miR-653. The binding sequences between miR-653 and CXCR5 were predicted using the TargetScan website and confirmed using a luciferase reporter assay. Reverse transcription-quantitative PCR was used to determine the mRNA expression levels of miR-653 and CXCR5 in ACHN cells transfected with NC mimic, miR-653 mimic, and miR-653 inhibitor. All data are presented as the mean ± SD. *P<0.05; **P<0.01; ***P<0.001. miRNA, microRNA; sh, short hairpin; NC, negative control; CXCR5, C-X-C motif chemokine receptors 5.

CXCR5 mediates PLK1S1/miR-653-regulated renal cell carcinoma tumorigenesis. Reverse transcription-quantitative PCR was used to determine the relative mRNA expression of CXCR5 in (A) ACHN cells transfected with shNC, shPLK1S1, shPLK1S1 plus CXCR5 and (B) ACHN cells transfected with NC mimic, miR-653 mimic, and miR-653 mimic plus CXCR5. Matrigel assay was used to investigate cell invasion in ACHN cells transfected with (C) shNC, shPLK1S1, shPLK1S1 plus CXCR5 and (D) NC mimic, miR-653 mimic, miR-653 mimic plus CXCR5 and the results were subsequently quantified. Colony formation assay was used to determine the colony number of ACHN cells transfected with (E) shNC, shPLK1S1, shPLK1S1 plus CXCR5 and (G) NC mimic, miR-653 mimic, miR-653 mimic plus CXCR5 and the results were subsequently quantified. All data are presented as the mean ± SD. *P<0.05; **P<0.01. miRNA, microRNA; sh, short hairpin; NC, negative control; CXCR5, C-X-C motif chemokine receptors 5.

RCC cells to sorafenib was assessed. As shown in Fig. 7A, CXCR5 increased the cell viability of sorafenib-resistant ACHN cells expressing shPLK1S1 or miR-653 mimic in the presence of sorafenib treatment. In addition, overexpression of CXCR5 reduced the inhibitory effect of shPLK1S1 or miR-653 mimic on IC50 values in sorafenib-resistant RCC cells (Fig. 7B and C). The TUNEL assay showed that overexpression of CXCR5 significantly reversed shPLK1S1 or miR-653 mimic-mediated promotion of cell apoptosis in ACHN-R cells following sorafenib treatment (Fig. 7D-G). Taken together, the data indicate that CXCR5 is a key effector of PLK1S1 and miR-653-regulated sorafenib resistance in RCC cells.

PLK1S1 knockdown prevents tumor growth in vivo. To further determine whether PLK1S1 promotes RCC growth in vivo, the xenograft experiment was performed. The results demonstrated that PLK1S1 knockdown significantly reduced the growth of the tumor compared with that in the shNC group.
RT-qPCR showed that the mRNA expression level of PLK1S1 was significantly decreased in the shPLK1S1 group compared with that in the shNC group, while the expression level of miR-653 was significantly increased in the shPLK1S1 group compared with that in the shNC group (Fig. 8D and E). Furthermore, western blot analysis demonstrated that knockdown of PLK1S1 reduced the protein expression level of CXCR5 (Fig. 8F). In summary, these data reveal that PLK1S1 promotes tumor growth of RCC via the miR-653/CXCR5 axis.

**Discussion**

The present study revealed that PLK1S1 promoted RCC tumorigenesis and enhanced sorafenib resistance of RCC...
Let al: PLK1S1/miR-653 PROMOTES RENAL CELL CARCINOMA PROGRESSION

Through the miR-653/CXCR5 axis (Fig. 9). The present study not only discovered a novel regulatory mechanism in RCC, but also identified a potential novel therapy for patients with RCC.

Over the last decade, lncRNAs have attracted increasing attention and demonstrated their pivotal roles in various types of cancer, including RCC. For example, Dong et al. (26) reported that lncRNA SNHG7 promoted proliferation and inhibited apoptosis of RCC cells by inhibiting the protein expression level of CDKN1A. Yue et al. (27) revealed that the knockdown of lncRNA DLEU1 inhibited RCC progression by regulating the Akt and EMT signaling pathway. In the present study, it was demonstrated that PLK1S1 was upregulated in RCC tissues and cells, and that high expression of PLK1S1 was associated with an advanced TNM stage and poor prognosis in patients with RCC.

The competing endogenous RNA (ceRNA) network exhibits its regulatory function in human cancer, including RCC. For example, Yang et al. (28) found that the lncRNA TUG1 acted as a ceRNA of miR-196a to accelerate the proliferation, migration and invasion of RCC. Shi et al. (29) demonstrated that the lncRNA ROR sponged miR-206 to promote RCC progression through increasing the protein expression level of VEGF. Furthermore, Xie et al. (17) demonstrated that hsa_circ_0004771 facilitated the proliferation and inhibited apoptosis in breast cancer by functioning as a ceRNA of miR-653 to regulate the ZEB2 signaling pathway. In the present study, it was confirmed that miR-653 had the ability to bind to PLK1S1. To the best of our knowledge this is the first time that the sponging effect of PLK1S1 on miR-653 in RCC has been discovered. In addition, the inhibitory effects of shPLK1S1 on RCC progression and chemoresistance of
RCC cells to sorafenib were reduced by the miR-653 inhibitor. Therefore, to the best of our knowledge it has been demonstrated for the first time that PLK1S1 acted as a ceRNA to sponge miR-653 to promote tumorigenesis and enhance the chemoresistance of RCC.

CXCRs, comprising of CXCR 1 to 7, are not only involved in the immune system but also in tumorigenesis and cancer development (30). For example, Saintigny et al (31) found that CXCR2 was associated with a low 5-year survival rate and promoted the invasion and metastasis of lung adenocarcinoma. Furthermore, Sun et al (32) reported that the knockdown of CXCR2 and CXCR3 suppressed the migration, invasion, colony formation and sphere-forming abilities of RCC cells. CXCR5 has been reported to be upregulated in ccRCC, and CXCR5 knockdown reduced the promoting effect of CXCL13 on the proliferation and migration of ccRCC cells (22). However, there are no previous studies that investigated the involvement of CXCR5 in RCC.

In the present study, it was found that CXCR5 was a target of miR-653. In addition, the overexpression of CXCR5 rescued PLK1S1 knockdown- or miR-653 mimic-attenuated progression and chemoresistance of RCC cells, suggesting that CXCR5 was crucial for PLK1S1/miR-653-regulated progression of RCC.

In conclusion, the present study reported the potential molecular mechanisms of PLK1S1 in the tumorigenesis and chemoresistance of RCC. To the best of our knowledge it has been demonstrated for the first time that PLK1S1 contributed to RCC progression and enhanced the chemosensitivity of RCC cells via the miR-653/CXCR5 pathway. The results provide a further understanding in the treatment of RCC using a PLK1S1-targeted approach. However, further investigation is still required. Firstly, other lncRNAs may exist and serve as ceRNAs to regulate crucial gene expression in RCC. Secondly, PLK1S1 can bind to a number of miRNAs, of which, other miRNAs can also affect the development of RCC.

Acknowledgements

Not applicable.

Funding

This study was supported by the Science and Technology Committee of Changning District of Shanghai (grant no. CNKW2018Y03).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

WL, DL and ML designed the present study. DY and YZ and SZ performed all the experiments. WL and ML analyzed the data and prepared the figures. WL and DL drafted the initial manuscript. ML reviewed and revised the manuscript. All authors approved the final version of the manuscript.

Ethics approval and consent to participate

All in vivo experimental procedures were approved by the Ethics Committee of Shanghai Jiaotong University School of Medicine.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Capitanio U, Bensalah K, Bes A, Boorjian SA, Bray F, Coleman J, Gore JL, Sun M, Wood C and Russo P: Epidemiology of renal cell carcinoma. Eur Urol 75: 74-84, 2019.
2. Rini BI, Campbell SC and Escudier B: Renal cell carcinoma. Lancet 373: 1119-1132, 2009.
3. Brugarolas J: Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med 356: 185-187, 2007.
4. Schmitt AM and Chang HY: Long noncoding RNAs in cancer pathways. Cancer Cell 29: 452-463, 2016.
5. Huarte M: The emerging role of IncRNAs in cancer. Nat Med 21: 1253-1261, 2015.
6. Li M, Wang Y, Cheng L, Niu W, Zhao G, Raju JK, Hua J, Wu B, Yin B, Song Y and Bu R: Long non-coding RNAs in renal cell carcinoma: A systematic review and clinical implications. Oncotarget 8: 48424-48435, 2017.
7. Zhai W, Sun Y, Guo C, Hu G, Wang M, Zheng J, Lin W, Huang Q, Li G, Zheng J and Chang C: lncRNA-SAREC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals. Cell Death Differ 24: 1502-1517, 2017.
8. Huang T, Wang X, Yang X, Ji J, Wang Q, Yue X and Dong Z: Long non-coding RNA DUXAP8 enhances renal cell carcinoma progression via downregulating miR-126. Med Sci Monit 24: 7340-7347, 2018.
9. Xu Z, Yang F, Wei D, Liu B, Chen C, Bao Y, Wu Z, Wu D, Tan H, Li J, et al: Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma. Oncogene 36: 1965-1977, 2017.
10. Xue X, Yang YA, Zhang A, Fong KW, Kim J, Song B, Li S, Zhao JC and Yu J: LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene 35: 2746-2755, 2016.
11. Peng P, Wang R, Zhang Y, Zhao Z, Zhou W, Zhang Z, Liang H, Zhao W, Qi L, Guo Z and Gu Y: Differential expression analysis at the individual level reveals a LncRNA prognostic signature for lung adenocarcinoma. Mol Cancer 16: 98, 2017.
12. Dat Le T, Matsuo T, Yoshimaru T, Kakiuuchi S, Goto H, Hanibuchi M, Kuramoto T, Nishioka Y, Sone S and Katagiri T: Identification of genes potentially involved in bone metastasis by genome-wide gene expression profile analysis of non-small cell lung cancer in mice. Int J Oncol 40: 1435-1469, 2012.
13. Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714, 2009.
14. Wang RT, Xu M, Xu CX, Song ZG and Jin H: Decreased expression of miR216a contributes to non-small-cell lung cancer progression. Clin Cancer Res 20: 4705-4716, 2014.
15. Wang ZZ, Luo YR, Du J, Yu Y, Yang XZ, Cui YJ and Jin XF: MiR-296-5p inhibits cell invasion and migration of esophageal squamous cell carcinoma by downregulating STAT3 signaling. Eur Rev Med Pharmacol Sci 23: 5206-5214, 2019.
16. Han W, Wang L, Zhang L, Wang Y and Li Y: Circular RNA circ-RAD23B promotes cell growth and invasion by miR-593-3p/CCND2 and miR-653-5p/TIAM1 pathways in non-small cell lung cancer. Biochem Biophys Res Commun 510: 462-466, 2019.
17. Xie R, Tang J, Zhu X and Jiang H: Silencing of hsa_circ_004771 inhibits proliferation and induces apoptosis in breast cancer through activation of miR-653 by targeting ZEB2 signaling pathway. Biosci Rep 39: BSR20181919, 2019.
18. Lin CY, Chen YM, Hsu HH, Shiu CT, Kuo HC and Chen TY: Grouper (epinephelus coioides) CXCR4 is expressed in response to pathogens infection and early stage of development. Dev Comp Immunol 36: 112-120, 2012.

19. Zhao K, Yao Y, Luo X, Lin B, Huang Y, Zhou Y, Li Z, Guo Q and Lu N: LY-202 inhibits activation of endothelial cells and angiogenesis through CXCL12/CXCR7 pathway in breast cancer. Carcinogenesis 39: 588-600, 2018.

20. Yang J, Tang H, Huang J and An H: Upregulation of CXCR7 is associated with poor prognosis of prostate cancer. Med Sci Monit 24: 5185-5191, 2018.

21. Bates RC, DeLeo MJ III and Mercurio AM: The epithelial-mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. Exp Cell Res 299: 315-324, 2004.

22. Zheng Z, Cai Y, Chen H, Chen Z, Zhu D, Zhong Q and Xie W: CXCL13/CXCR5 axis predicts poor prognosis and promotes progression through PI3K/AKT/mTOR pathway in clear cell renal cell carcinoma. Front Oncol 8: 682, 2018.

23. Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama S, MacLennan G and Novick A: TNM staging of renal cell carcinoma. Workgroup no. 3. Union international contre le cancer (UICC) and the American joint committee on cancer (AJCC). Cancer 80: 992-993, 1997.

24. Sobin LH and Fleming ID: TNM classification of malignant tumors, fifth edition (1997). Union internationale contre le cancer and the American joint committee on cancer. Cancer 80: 1803-1804, 1997.

25. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

26. Dong JS, Wu B and Jiang B: LncRNA SNHG7 promotes the proliferation and inhibits apoptosis of renal cell cancer cells by downregulating CDKN1A. Eur Rev Med Pharmacol Sci 23: 10241-10247, 2019.

27. Yue G, Chen C, Bai L, Wang G, Huang Y, Wang Y, Cui H and Xiao Y: Knockdown of long noncoding RNA DLEU1 suppresses the progression of renal cell carcinoma by downregulating the Akt pathway. Mol Med Rep 20: 4551-4557, 2019.

28. Yang Y, Sun DM, Yu JF, Zhang M, Yi C, Yang R, Dan BH and Li AJ: Long noncoding RNA TUG1 promotes renal cell carcinoma cell proliferation, migration and invasion by down-regulating microRNA196a. Mol Med Rep 18: 5791-5798, 2018.

29. Shi J, Zhang D, Zhong Z and Zhang W: LncRNA ROR promotes the progression of renal cell carcinoma through the miR-206/VEGF axis. Mol Med Rep 20: 3782-3792, 2019.

30. Yu C and Zhang Y: Characterization of the prognostic values of CXCR family in gastric cancer. Cytokine 123: 154785, 2019.

31. Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, et al: CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 73: 571-582, 2013.

32. Sun KH, Sun GH, Wu YC, Ko BJ, Hsu HT and Wu ST: TNF-α augments CXCR2 and CXCR3 to promote progression of renal cell carcinoma. J Cell Mol Med 20: 2020-2028, 2016.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.